Efficacy

Efficacy of Adcetris (brentuximab vedotin) in Lymphoma

Adcetris (brentuximab vedotin) is an antibody-drug conjugate specifically indicated for the treatment of certain types of lymphoma, including Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). In clinical trials, Adcetris has shown significant efficacy in patients with relapsed or refractory HL after autologous hematopoietic stem cell transplantation (HSCT). The pivotal phase II study demonstrated an overall response rate (ORR) of 75% in this patient population, with a complete remission (CR) rate of 34%. For patients with sALCL, Adcetris achieved an ORR of 86% and a CR rate of 57% in a phase II clinical trial. These results have established Adcetris as an effective treatment option for patients with relapsed or refractory HL and sALCL.

Efficacy of Adcetris in Combination Therapies for Lymphoma

Adcetris has also been evaluated in combination with other chemotherapeutic agents. A phase III trial assessing the efficacy of Adcetris in combination with chemotherapy for frontline treatment of advanced classical HL showed a significant improvement in modified progression-free survival compared to the standard chemotherapy regimen alone. The combination therapy led to a two-year modified progression-free survival rate of 82.1% compared to 77.2% with standard therapy, highlighting the potential of Adcetris in improving treatment outcomes when used as part of a combination regimen in newly diagnosed HL.

Efficacy of Polivy (polatuzumab vedotin-piiq) in Lymphoma

Polivy (polatuzumab vedotin-piiq) is another antibody-drug conjugate approved for the treatment of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma. It is indicated for use in combination with bendamustine and a rituximab product in patients who have relapsed or refractory DLBCL after at least two prior therapies. In a pivotal phase Ib/II clinical trial, the combination including Polivy showed an ORR of 40% with a CR rate of 24% in patients with relapsed or refractory DLBCL. These outcomes are particularly noteworthy considering the poor prognosis associated with this patient population and the limited treatment options available.

Conclusion

Both Adcetris and Polivy have demonstrated efficacy in the treatment of different types of lymphoma, with Adcetris being particularly effective in HL and sALCL, and Polivy showing promise in DLBCL. Their roles as part of combination therapies have also been established, leading to improved outcomes in patients with these challenging conditions. Continued research and clinical trials are expected to further define the utility of these antibody-drug conjugates in the management of lymphoma and potentially expand their indications.